Objective: To evaluate the efficacy and safety of unfractionated heparin associated with mechanical prophylaxis as a method for preventing venous thromboembolism in hip arthroplasty.
Method: We retrospectively reviewed the records of 181 hip arthroplasties out of 216 consecutive cases performed over a period of 39 months in our hospital. We excluded 35 cases due to non-adherence to the standardized method of thromboprophylaxis or loss to follow-up. All arthroplasties evaluated completed one-year follow-up after surgery with five consultations at predefined periods. Efficacy of the proposed method was evaluated by the occurrence of symptomatic venous thromboembolism confirmed by specific tests and safety was determined by the lack of occurrence of major bleeding according to criteria established by the International Society on Thrombosis and Haemostasis.
Results: There were four cases of symptomatic venous thromboembolism (2.2%), with three cases of deep vein thrombosis (1.65%) and one case of pulmonary embolism (0.55%). We found one case of severe bleeding (0.55%).
Conclusion: Unfractionated heparin associated with mechanical prophylaxis proved to be an effective and safe method for preventing venous thromboembolism in patients undergoing hip arthroplasty, presenting rates of thromboembolic complications and major bleeding within the range reported with other methods currently used of thromboprophylaxis. Level of Evidence IV, Case Series.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544530 | PMC |
http://dx.doi.org/10.1590/1413-785220152304144314 | DOI Listing |
Curr Opin Oncol
January 2025
Paris Cité University, Assistance-Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Interne, Hôpital Louis-Mourier, Inserm, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France.
Purpose Of Review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.
View Article and Find Full Text PDFPurpose: To evaluate longer term outcomes of the Zilver Vena Venous Stent in patients undergoing venous stenting.
Materials And Methods: Patients with iliofemoral obstructive venous disease and treated with venous stents were retrospectively enrolled in a physician-led real-world data collection effort. Results were analyzed by etiologies: post-thrombotic syndrome (PTS), non-thrombotic iliac vein lesion (NIVL), and iliocaval acute deep vein thrombosis (aDVT).
Cochrane Database Syst Rev
January 2025
Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, USA.
Background: People undergoing major orthopaedic surgery are at increased risk of postoperative thromboembolic events. Low molecular weight heparins (LMWHs) are recommended for thromboprophylaxis in this population. New oral anticoagulants, including direct factor Xa inhibitors, are recommended as alternatives.
View Article and Find Full Text PDFRes Pract Thromb Haemost
January 2025
Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo Universitaire de St-Etienne, Saint-Etienne, France.
Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event.
Objectives: To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients.
Methods: An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge.
Blood Vessel Thromb Hemost
December 2024
Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!